Haytham El-Sakka1, Omar Kujan2, Camile S Farah3. 1. UWA Dental School, University of Western Australia, Nedlands, WA, Australia. 2. UWA Dental School, University of Western Australia, Nedlands, WA, Australia. Electronic address: omar.kujan@uwa.edu.au. 3. UWA Dental School, University of Western Australia, Nedlands, WA, Australia; Australian Centre for Oral Oncology Research & Education, UWA Dental School, The University of Western Australia, Nedlands, WA, Australia.
Abstract
OBJECTIVES: This paper aims to systematically review current findings on altered expression of miRNAs in OPMDs and whether they can be used as risk stratification biomarkers. METHODS: Studies were collated after searching three different electronic databases: PubMed, Embase, Medline. Additional searches were carried out through cross checking the bibliographies of selected articles. After a thorough selection process made by two of the authors, 40 articles met the inclusion criteria and were included in the review. Studies were assessed and analysed in terms of how the candidate miRNA biomarkers were differentially expressed and validated. RESULTS: The included studies examined the expression of miRNAs from human specimens (blood serum/plasma, saliva, tissue) as diagnostic or prognostic biomarkers in patients with OPMDs, some of which have been utilised as risk stratification biomarkers for malignant transformation and have showed promising findings. CONCLUSION: The current evidence to support or refute the prognostic utility of miRNAs in predicting cancer progression in OPMDs is equivocal. Further longitudinal prospective studies with solid study design are warranted.
OBJECTIVES: This paper aims to systematically review current findings on altered expression of miRNAs in OPMDs and whether they can be used as risk stratification biomarkers. METHODS: Studies were collated after searching three different electronic databases: PubMed, Embase, Medline. Additional searches were carried out through cross checking the bibliographies of selected articles. After a thorough selection process made by two of the authors, 40 articles met the inclusion criteria and were included in the review. Studies were assessed and analysed in terms of how the candidate miRNA biomarkers were differentially expressed and validated. RESULTS: The included studies examined the expression of miRNAs from human specimens (blood serum/plasma, saliva, tissue) as diagnostic or prognostic biomarkers in patients with OPMDs, some of which have been utilised as risk stratification biomarkers for malignant transformation and have showed promising findings. CONCLUSION: The current evidence to support or refute the prognostic utility of miRNAs in predicting cancer progression in OPMDs is equivocal. Further longitudinal prospective studies with solid study design are warranted.
Authors: Andrea Carenzo; Mara S Serafini; Elisa Roca; Alberto Paderno; Davide Mattavelli; Chiara Romani; Pierre Saintigny; Senada Koljenović; Lisa Licitra; Loris De Cecco; Paolo Bossi Journal: Cells Date: 2020-08-03 Impact factor: 6.600
Authors: Yiran Peng; Shoushan Hu; Kun Zhang; Yuru Wang; Maierdanjiang Rouzi; Dan Zhou; Ran Yang Journal: Cancer Manag Res Date: 2021-06-17 Impact factor: 3.989